Scientists have identified five specific blood proteins that can accurately predict a person's risk for developing a serious ...

For the period, Gilead's revenue clocked in at $6.67 billion, essentially flat over the same quarter of 2024. The company attributed this to sales declines of COVID drug Veklury and oncology products.

Two of Gilead Sciences' most important drugs missed sales expectations late Thursday. Gilead stock fell early Friday.